HGS shares dip on FDA delay

Shares of Human Genome Sciences took a small hit Friday evening after the biotech company said that the FDA was extending its review time for the closely-watched lupus drug benlysta. While the drug was endorsed recently by an FDA panel, it's no great surprise that the agency needed more time to review the therapy as well as the panel vote. The target date for an agency decision is now March 10. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.